DK2473053T3 - Substituerede xanthinderivater - Google Patents
Substituerede xanthinderivater Download PDFInfo
- Publication number
- DK2473053T3 DK2473053T3 DK10814504.6T DK10814504T DK2473053T3 DK 2473053 T3 DK2473053 T3 DK 2473053T3 DK 10814504 T DK10814504 T DK 10814504T DK 2473053 T3 DK2473053 T3 DK 2473053T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- compounds
- deuterium
- disease
- cas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
Claims (10)
1. Forbindelse med følgende formel:
eller et farmaceutisk acceptabelt salt deraf, hvor isotopberigelsesfaktoren for hvert angivne deuteriumatom er mindst 5000.
2. Forbindelse ifølge krav 1, hvor ethvert atom, der ikke er angivet som deuterium, er til stede i dets naturlige isotoptalrighed.
3. Forbindelse ifølge krav 2, hvor isotopberigelsesfaktoren for hvert angivne deuteriumatom er mindst 6000.
4. Forbindelse ifølge krav 2, hvor isotopberigelsesfaktoren for hvert angivne deuteriumatom er mindst 6600.
5. Forbindelse ifølge et hvilket som helst af kravene 1 til 4, hvor forbindelsen omfatter mindre end 10 % af den anden stereoisomer.
6. Forbindelse ifølge krav 5, hvor forbindelsen omfatter mindre end 5 % af den anden stereoisomer.
7. Farmaceutisk præparat, der omfatter en forbindelse ifølge et hvilket som helst af kravene 1 til 6 og et farmaceutisk acceptabelt bæremateriale.
8. Forbindelse ifølge et hvilket som helst af kravene 1 til 6 til anvendelse til behandling af en sygdom eller tilstand, der er udvalgt blandt diabetisk nefropati, hypertensiv nefropati eller dysbasi som følge af kronisk okklusiv arteriesygdom i ekstremiteterne.
9. Forbindelse ifølge et hvilket som helst af kravene 1 til 6 til anvendelse til behandling af kronisk nyresygdom.
10. Forbindelse til anvendelse ifølge krav 9, hvor den kroniske nyresygdom er glomerulonephritis, fokal segmental glomerulosklerose, nefrotisk syndrom, reflux uropati eller polycystisk nyresygdom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23934209P | 2009-09-02 | 2009-09-02 | |
US12/873,991 US20110053961A1 (en) | 2009-02-27 | 2010-09-01 | Substituted xanthine derivatives |
PCT/US2010/047708 WO2011028922A1 (en) | 2009-09-02 | 2010-09-02 | Substituted xanthine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2473053T3 true DK2473053T3 (da) | 2015-07-27 |
Family
ID=43625765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10814504.6T DK2473053T3 (da) | 2009-09-02 | 2010-09-02 | Substituerede xanthinderivater |
Country Status (22)
Country | Link |
---|---|
US (1) | US20110053961A1 (da) |
EP (2) | EP2473053B1 (da) |
JP (1) | JP5292516B2 (da) |
KR (1) | KR101591137B1 (da) |
CN (2) | CN102480968B (da) |
AU (1) | AU2010289465B2 (da) |
BR (1) | BR112012008108B1 (da) |
CA (1) | CA2771123C (da) |
DK (1) | DK2473053T3 (da) |
EA (1) | EA023809B1 (da) |
ES (1) | ES2542401T3 (da) |
HK (1) | HK1170377A1 (da) |
HR (1) | HRP20150797T1 (da) |
HU (1) | HUE026800T2 (da) |
IN (1) | IN2012DN01641A (da) |
ME (1) | ME02177B (da) |
MX (1) | MX2012002705A (da) |
PL (1) | PL2473053T3 (da) |
PT (1) | PT2473053E (da) |
SI (1) | SI2473053T1 (da) |
WO (1) | WO2011028922A1 (da) |
ZA (1) | ZA201201295B (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090239886A1 (en) * | 2008-02-29 | 2009-09-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
WO2010075086A2 (en) * | 2008-12-15 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Pyrrolidinone inhibitors of pde-4 |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
US9260432B2 (en) | 2009-09-02 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
JP2013503883A (ja) * | 2009-09-02 | 2013-02-04 | コンサート ファーマシューティカルズ インコーポレイテッド | 置換キサンチン誘導体 |
WO2012031072A1 (en) | 2010-09-01 | 2012-03-08 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
US9074233B2 (en) | 2010-09-01 | 2015-07-07 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
EP2611807A2 (en) * | 2010-09-01 | 2013-07-10 | Concert Pharmaceuticals Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione |
IN2014DN08443A (da) | 2012-04-13 | 2015-05-08 | Concert Pharmaceuticals Inc | |
WO2013159006A1 (en) * | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione |
US20170216296A1 (en) * | 2014-04-18 | 2017-08-03 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
WO2015175008A1 (en) * | 2014-05-14 | 2015-11-19 | Concert Pharmaceuticals, Inc. | Methods of treating chronic kidney disease characterized by macroalbuminuria |
WO2015184248A1 (en) * | 2014-05-30 | 2015-12-03 | Concert Pharmaceuticals, Inc. | Methods of treating fibrotic diseases |
AU2015330490B2 (en) | 2014-10-09 | 2018-08-09 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and applications thereof |
CN105566324B (zh) * | 2014-10-09 | 2020-04-03 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
JP6511692B2 (ja) * | 2015-05-20 | 2019-05-15 | グアンドン レイノベント バイオテック カンパニー リミテッド | ヒドロキシプリン類化合物及びその応用 |
CN108137592B (zh) * | 2015-11-03 | 2021-03-05 | 纽弗姆制药有限公司 | 用于治疗血癌的氘代化合物以及其组合物和方法 |
CN108699061B (zh) * | 2015-11-16 | 2022-07-05 | 纽弗姆制药有限公司 | 用于治疗血液恶性肿瘤、炎症和自身免疫性疾病的氘代化合物 |
CN114727983A (zh) * | 2019-09-25 | 2022-07-08 | 金翅雀生物公司 | 黄嘌呤cb1抑制剂 |
CN111440041B (zh) * | 2020-05-19 | 2021-03-05 | 北京理工大学 | 一种甲苯-d8的合成方法 |
CN114380829A (zh) * | 2021-12-28 | 2022-04-22 | 赤峰万泽药业股份有限公司 | 一种己酮可可碱及其合成方法和应用 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE793059A (fr) | 1972-02-28 | 1973-04-16 | Ritzerfeld Gerhard | Dispositif d'encrage pour presses rotatives a |
JPS5632477B2 (da) | 1973-03-07 | 1981-07-28 | ||
DE2330742C2 (de) | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
JPS5610188B2 (da) | 1973-09-14 | 1981-03-06 | ||
JPS5756481B2 (da) | 1974-06-13 | 1982-11-30 | ||
CA1037234A (en) | 1976-06-01 | 1978-08-29 | Aluma Building Systems Incorporated | Wall forming structure for poured concrete walls |
FR2376188A1 (fr) | 1976-12-28 | 1978-07-28 | Elf Union | Procede de preparation de compositions de bitumes polymeres |
JPS54120627A (en) | 1978-03-13 | 1979-09-19 | Nittetsu Kakoki Kk | Regenaration of asphalt concrete |
JPS5576876A (en) | 1978-12-05 | 1980-06-10 | Grelan Pharmaceut Co Ltd | Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne |
JPS5581055A (en) | 1978-12-12 | 1980-06-18 | Kubota Ltd | Drawing device of pipe |
JPS55122779A (en) | 1979-03-13 | 1980-09-20 | Maruko Seiyaku Kk | Preparation of theobromine derivative |
CS201558B1 (en) | 1979-05-14 | 1980-11-28 | Pavol Kovar | Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine |
JPS5677279A (en) | 1979-11-28 | 1981-06-25 | Ota Seiyaku Kk | Preparation of xanthine derivative |
JPS56125451A (en) | 1980-03-08 | 1981-10-01 | Mitsubishi Gas Chem Co Inc | Production of modified asphalt |
JPS5762278A (en) | 1980-10-01 | 1982-04-15 | Sagami Chem Res Center | Theobromine derivative and its preparation |
JPS5780385A (en) | 1980-11-05 | 1982-05-19 | Mitsubishi Petrochem Co Ltd | Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine |
JPS5785387A (en) | 1980-11-14 | 1982-05-28 | Teikoku Chem Ind Corp Ltd | Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine |
JPS5798284A (en) | 1980-12-10 | 1982-06-18 | Kawashima Yakuhin Kaihatsu Kk | Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine |
JPS5838284B2 (ja) | 1981-04-14 | 1983-08-22 | ミサワホ−ム株式会社 | 脱型装置 |
JPS57200391A (en) | 1981-06-02 | 1982-12-08 | Daito Koeki Kk | 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine |
JPS58134092A (ja) | 1982-02-05 | 1983-08-10 | Sagami Chem Res Center | テオブロミン誘導体 |
JPS58150594A (ja) | 1982-03-03 | 1983-09-07 | Daito Koeki Kk | キサンチン誘導体の製造方法 |
CS237719B1 (cs) | 1983-05-12 | 1985-10-16 | Jan Jendrichovsky | SpAsob přípravy dimetyl-(5-oxohexyl)-xantlnov |
DE3508097A1 (de) | 1984-07-21 | 1986-02-06 | Hoechst Ag, 6230 Frankfurt | Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung |
DD274334A3 (de) | 1985-12-17 | 1989-12-20 | Dresden Arzneimittel | Verfahren zur herstellung von reinem 3,7-dimethyl-1-(5-oxohexyl)-xanthin |
IL106861A (en) | 1986-12-31 | 1997-02-18 | Hoechst Roussel Pharma | Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines |
CS263595B1 (en) | 1988-01-06 | 1989-04-14 | Rybar Alfonz | Process for preparing 7-n-propyl-3-methyl-3,7-dihydro-1h-purin-2,6-dione |
JP2661666B2 (ja) | 1988-02-19 | 1997-10-08 | ヘキスト薬品工業株式会社 | 抗消化性潰瘍剤 |
IT1231779B (it) | 1989-08-09 | 1991-12-21 | Eniricerche Spa | Procedimento per l'ossidazione di composti paraffinici. |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
DE3942872A1 (de) | 1989-12-23 | 1991-06-27 | Hoechst Ag | Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen |
US5112827A (en) | 1990-05-18 | 1992-05-12 | Board Of Regents, The University Of Texas System | Drug to reverse fatty liver and atheromatous lesions |
WO1992007566A2 (en) | 1990-11-01 | 1992-05-14 | Board Of Regents, The University Of Texas System | Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues |
EP0484785B1 (en) | 1990-11-07 | 1996-05-22 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses |
IL100194A0 (en) | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans |
IL100195A0 (en) | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament having immuno suppressing activity |
US5763446A (en) | 1992-03-26 | 1998-06-09 | University Of Southern California | Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases |
US5780476A (en) * | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
HUT68560A (en) | 1993-08-02 | 1995-04-27 | Chinoin Gyogyszer Es Vegyeszet | The use of xantine derivatives for promotion of healing of operative lesions |
KR100477070B1 (ko) * | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
JPH10507156A (ja) | 1994-05-16 | 1998-07-14 | セル・セラピューティックス・インコーポレーテッド | キラル第二級アルコールの不斉合成 |
DE4430128A1 (de) | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
WO1996005836A2 (en) | 1994-08-25 | 1996-02-29 | Medical University Of South Carolina | Methods of treating cold symptoms using pentoxifylline |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
DE19544768C1 (de) | 1995-11-30 | 1997-07-10 | Rentschler Arzneimittel | Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
US5985592A (en) | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
US6248889B1 (en) | 1998-11-20 | 2001-06-19 | 3M Innovative Properties Company | Process for converting an alcohol to the corresponding fluoride |
US6417208B1 (en) | 1999-02-05 | 2002-07-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of identification of inhibitors of PDE1C |
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
GB0102107D0 (en) | 2001-01-26 | 2001-03-14 | Syngenta Ltd | Chemical process |
NZ528689A (en) | 2001-05-03 | 2005-03-24 | F | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
WO2003013568A1 (en) | 2001-08-02 | 2003-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Cytokine modulation therapy |
KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
JP2005527524A (ja) | 2002-03-14 | 2005-09-15 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Pde11a阻害剤を用いる糖尿病の処置方法 |
DE10214228A1 (de) | 2002-03-22 | 2003-10-02 | Bdd Group Holding Ag Zug | Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel |
US20050107420A1 (en) * | 2002-05-23 | 2005-05-19 | Boehringe Ingelheim Pharma Gmbh & Co. Kg | Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
UA86591C2 (ru) | 2003-06-30 | 2009-05-12 | Алтана Фарма Аг | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе |
WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
CA2568929A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
CA2581775A1 (en) | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Dihydropyrimidine microcapsule - formulations |
AU2005292339A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
AU2006299424A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties |
US20090239886A1 (en) * | 2008-02-29 | 2009-09-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
-
2010
- 2010-09-01 US US12/873,991 patent/US20110053961A1/en not_active Abandoned
- 2010-09-02 PL PL10814504T patent/PL2473053T3/pl unknown
- 2010-09-02 EP EP20100814504 patent/EP2473053B1/en active Active
- 2010-09-02 WO PCT/US2010/047708 patent/WO2011028922A1/en active Application Filing
- 2010-09-02 EP EP15163741.0A patent/EP2963040A1/en not_active Withdrawn
- 2010-09-02 CA CA2771123A patent/CA2771123C/en active Active
- 2010-09-02 CN CN201080039090.5A patent/CN102480968B/zh active Active
- 2010-09-02 BR BR112012008108A patent/BR112012008108B1/pt active IP Right Grant
- 2010-09-02 AU AU2010289465A patent/AU2010289465B2/en active Active
- 2010-09-02 IN IN1641DEN2012 patent/IN2012DN01641A/en unknown
- 2010-09-02 DK DK10814504.6T patent/DK2473053T3/da active
- 2010-09-02 HU HUE10814504A patent/HUE026800T2/en unknown
- 2010-09-02 MX MX2012002705A patent/MX2012002705A/es active IP Right Grant
- 2010-09-02 EA EA201270339A patent/EA023809B1/ru not_active IP Right Cessation
- 2010-09-02 JP JP2012528054A patent/JP5292516B2/ja active Active
- 2010-09-02 ES ES10814504.6T patent/ES2542401T3/es active Active
- 2010-09-02 CN CN201410746544.2A patent/CN104478881A/zh active Pending
- 2010-09-02 ME MEP-2015-108A patent/ME02177B/me unknown
- 2010-09-02 SI SI201030985T patent/SI2473053T1/sl unknown
- 2010-09-02 PT PT108145046T patent/PT2473053E/pt unknown
- 2010-09-02 KR KR1020127008446A patent/KR101591137B1/ko active IP Right Grant
-
2012
- 2012-02-21 ZA ZA2012/01295A patent/ZA201201295B/en unknown
- 2012-11-05 HK HK12111125.1A patent/HK1170377A1/xx unknown
-
2015
- 2015-07-20 HR HRP20150797TT patent/HRP20150797T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CN102480968A (zh) | 2012-05-30 |
EA201270339A1 (ru) | 2012-09-28 |
HRP20150797T1 (hr) | 2015-09-11 |
CA2771123A1 (en) | 2011-03-10 |
WO2011028922A1 (en) | 2011-03-10 |
EP2473053A1 (en) | 2012-07-11 |
ME02177B (me) | 2015-10-20 |
CN102480968B (zh) | 2015-01-07 |
EA023809B1 (ru) | 2016-07-29 |
IN2012DN01641A (da) | 2015-06-05 |
ES2542401T3 (es) | 2015-08-05 |
AU2010289465A1 (en) | 2012-03-01 |
MX2012002705A (es) | 2012-04-02 |
CN104478881A (zh) | 2015-04-01 |
PL2473053T3 (pl) | 2015-10-30 |
PT2473053E (pt) | 2015-09-14 |
EP2473053B1 (en) | 2015-04-22 |
CA2771123C (en) | 2017-11-14 |
US20110053961A1 (en) | 2011-03-03 |
BR112012008108B1 (pt) | 2019-10-22 |
AU2010289465B2 (en) | 2016-03-10 |
HK1170377A1 (en) | 2013-03-01 |
EP2473053A4 (en) | 2013-03-27 |
JP2013503894A (ja) | 2013-02-04 |
KR20120050509A (ko) | 2012-05-18 |
JP5292516B2 (ja) | 2013-09-18 |
ZA201201295B (en) | 2012-10-31 |
EP2963040A1 (en) | 2016-01-06 |
HUE026800T2 (en) | 2016-07-28 |
KR101591137B1 (ko) | 2016-02-02 |
SI2473053T1 (sl) | 2015-10-30 |
BR112012008108A2 (pt) | 2015-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2473053T3 (da) | Substituerede xanthinderivater | |
US10335413B2 (en) | Substituted xanthine derivatives | |
JP5292413B2 (ja) | 置換キサンチン誘導体 | |
US8952016B2 (en) | Substituted xanthine derivatives | |
US9260432B2 (en) | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds | |
EP2836492B1 (en) | Substituted xanthine derivatives |